Sandoz unveils denosumab biosimilars in Europe
Basel: Sandoz has announced the European launch of Wyost (denosumab 120 mg) and Jubbonti (denosumab 60 mg).
The medicines are among the first denosumab biosimilars to launch in Europe and are approved by the European Commission to treat all indications of the reference medicines, Xgeva (denosumab 120 mg) and Prolia (denosumab 60 mg)
Wyost is approved for the treatment of cancer-related bone disease and Jubbonti is approved to treat osteoporosis.
It builds on other key biosimilar launches this year including Wyost and Jubbonti in the US and the recent launches of Tyruko (natalizumab) in the US and Afqlir (aflibercept) in Europe.
Christophe Delenta, President Europe, Sandoz, said, “We know that primary and secondary bone loss, and cancer-related bone events, place a significant burden on millions of patients and their families, as well as on European healthcare systems. That’s why the launch of these denosumab biosimilars is such an important milestone, expanding access to these potentially life-changing medicines and reinforcing our commitment to delivering sustainable treatment options for patients.”
Close to one quarter (4.14 million) of all newly reported cancer cases globally occur in Europe and cancer remains a leading cause of premature death for people aged 30-69 years in most European countries. Nearly all types of cancer can spread to the bone and cause pain and fractures, but cancers that often metastasize there include breast, lung and prostate.
According to the latest figures, 32 million people in Europe over 50 years old are estimated to live with osteoporosis, with the number of fractures per year set to increase by almost 25% by 2034. Only a minority of patients at high risk currently receive treatment, even after their first fracture.
The launch further expands the company’s presence in a global reference-medicine market worth a combined ~USD 6.6 billion8 and reinforces its established position in oncology and immunology.
